A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Entinostat (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms ENGAGE-501
- Sponsors Syndax Pharmaceuticals
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 19 Mar 2014 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015, as per ClinicalTrials.gov record.
- 31 Jul 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.